GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

Move over Ozempic, Wegovy, Mounjaro and Zepbound - Eli Lilly says another contender may be on the way. The pharmaceutical giant announced encouraging results from a Phase 3 clinical trial of its ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

A little-known provision in the Affordable Care Act allows patients to ask state-run panels to review decisions made by ...

Private health insurance premiums will be going up in 2026 — in some cases, by a lot. Congressional Democrats and Republicans ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of their body weight while reducing osteoarthritis pain.

Some patients dropped out of the trial early because they had lost so much weight.

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...